[Alpha beta-blockers for patients with hypertension].
Mizuta
Yoshihiko
Y
Third Department of Internal Medicine, Kurume University School of Medicine.
Imaizumi
Tsutomu
T
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use; D000077261:Carvedilol; D048909:Diabetes Complications / Q000188:drug therapy; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007741:Labetalol / Q000627:therapeutic use; D011379:Prognosis; D011412:Propanolamines / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D007741:Labetalol